FARN Share Price Performance

FARN Community Fair Values

View all narratives

Recent FARN News & Updates

No updates

Faron Pharmaceuticals Oy Key Details

Last Reported Earnings

Dec 31, 2024

Next Reporting Earnings

Aug 27, 2025

Earnings per share (EPS): -0.23
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: -121.0%

View full report ›

Faron Pharmaceuticals Oy Competitors

View more competitors

About FARN

Founded: 2003
Employees: 25
CEO: Juho Jalkanen
WebsiteView website: faron.com

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, it develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Finnish Market Performance

-0.6%

10.9%

7.4%

9.7%

In the last week, the market has been flat, with a notable exception in the Information Technology sector dropping 3.6%. As for the longer term, the market has risen 7.4% in the past 12 months. Looking forward, earnings are forecast to grow by 14% annually. Market details ›

Faron Pharmaceuticals Oy Share Price

FARN Share Price Performance

FARN Community Fair Values

Recent FARN News & Updates

Faron Pharmaceuticals Oy Key Details

Faron Pharmaceuticals Oy Competitors

The Big Beautiful Deficit

🎢 From Panic to Peak: Q2’s Wild Ride and What’s Next